Robert Anderson
Endocrinology, Diabetes & Metabolism · Omaha, NENPI 1225142367
Payments from drug & device makers
What this record shows
This record is dominated by education: $17 of the $17 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Shire North American Group Inc. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in NE, where the typical reported total is $1,422.
Across 1 payment — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shire North American Group Inc$17
Across 90 payments — averaging $8206.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$253K
- Novo Nordisk AS$174K
- AstraZeneca$164K
- Amgen$120K
- OPKO Pharmaceuticals, LLC$19K
- Eli Lilly$8K
What the payments were for
- Education$17100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shire North American Group Inc | 1 | $17 |
How this compares
$17 in reported general payments places this provider in the 5th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
See all endocrinology, diabetes & metabolism providers in Nebraska →
Other endocrinology, diabetes & metabolism in Omaha
- Marium IlahiOmaha$170K
- Cyrus DesouzaOmaha$86K
- Timothy WahlOmaha$41K
- Leslie EilandOmaha$17K
- Anupam KotwalOmaha$17K
- John GallagherOmaha$15K
- Andjela DrincicOmaha$14K
- Laura Graeff-ArmasOmaha$11K
- Claire BakerOmaha$6K
- Alain TaylonOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.